AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) | ANTX Stock NewsStockTitan·1 day ago, 01:33 PMANTX-8.24%
AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675PUBT·Sep 11 at 11:46 PMANTX-8.24%
The Fringe Playbook: Finding Strategic Leverage in Niche MarketsGlobal Report·Sep 9 at 10:12 AMINBS+1.52%ANTX-8.24%
Anthem (NASDAQ:ANTX) Director Robin Shane Readnour Sells 6,100 Shares of StockMarket Beat·Sep 9 at 01:08 AMANTX-8.24%
AN2 Therapeutics director Robin Shane Readnour reports disposal of common shares worth $97,645.76PUBT·Sep 8 at 11:43 PMANTX-8.24%
AN2 Therapeutics director Margaret M. FitzPatrick acquires 2,098 common shares worth $11,602.94PUBT·Sep 2 at 11:36 PMANTX-8.24%
Anthem (NASDAQ:ANTX) Director Margaret Fitzpatrick Purchases 2,098 SharesMarket Beat·Sep 2 at 11:08 PMANTX-8.24%
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting | ANTX Stock NewsStockTitan·Aug 31 at 02:00 PMANTX-8.24%
AN2 Therapeutics names Cameron Trenor III as chief medical officer in initial beneficial ownership filingPUBT·Aug 27 at 06:16 PMANTX-8.24%
AN2 Therapeutics director Robin Shane Readnour disposes of USD 212,486 common sharesPUBT·Aug 19 at 09:59 PMANTX-8.24%
